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Abstract 
    The oxidative cyclisation of a range of benzothieno[2,3-d]pyrimidine 
hydrazones (7a-e) to the 1,2,4-triazolo[4,3-c]pyrimidines (8a-e) catalysed by lithium 
iodide or to the 1,2,4-triazolo[1,5-c]pyrimidines (10a-e) with sodium carbonate is 
presented. A complementary synthesis of the 1,2,4-triazolo[1,5-c]pyrimidines (10a-e) 
starting from the amino imine 11 is also reported. The effect of these compounds on 
Shiga toxin (STx) trafficking in HeLa cells and comparison to the previously reported 
Exo2 is also detailed 
Keywords  Pyrimidyl hydrazone, triazolopyrimidine, lithium iodide, DMSO, sodium 
carbonate, Dimroth rearrangement, Exo2, Shiga toxin 
 
1. Introduction 
 Compounds containing the 5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine 
(1) nucleus have found many applications as adenosine mimics [1], analgesics [2], 
anticancer [3], antiviral agents [4], and as inhibitors of kinases [5] and human 
epidermal growth factor [6].  
Fig.1.  The 5,6,7,8-tetrahydro[1]benzothieno[2,3-d]pyrimidine core (1) and Exo2 (2) 
 
Exo2 (2) is a small molecule inhibitor of exocytosis that functions via the disruption 
of membrane trafficking [7]. This action also perturbs retrograde trafficking and as 
such, it has been used as a tool to help dissect the entry pathway of lipid binding 
bacterial toxins in mammalian cells [8,9]. Indeed, Exo2 has been shown to have a 
significant protective effect on HeLa cells against the protein synthesis inhibiting 
Shiga toxin (STx). Its effects on organelle morphology have suggested that its cellular 
target is involved in early endosome delivery to the TGN and/or TGN access to the 
Golgi stack [9]. By blocking delivery into the Golgi, Shiga toxin cannot reach the 
endoplasmic reticulum from where it normally translocates a membrane to reach its 
ribosome substrates in the cytosol.  
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This paper details our findings from the unexpected oxidative cyclisation of pyrimidyl 
hydrazones to give triazolopyrimidines, and includes a preliminary investigation on 
the ability of these new analogues of Exo2 to protect HeLa cells against a challenge 
by Shiga toxin. 
2. Chemistry 
During work on the synthesis of derivatives of Exo2 to discern structure 
activity relationships we required the hydrazone phenol (4). We had planned a simple 
deallylation of the ether (3) but concerned by the possible interference of the sulphur 
with palladium catalysed deallylation, we opted to use sodium iodide in dimethyl 
sulphoxide [10]. Instead of the expected deallylation a new compound was isolated 
 
Scheme 1. Oxidative cyclisation during attempted deprotection of allyloxy ether 
which still contained both the allyl and n-propyl ethers but lacked the NH and imine 
hydrogen of the hydrazone in 
1
Hnmr and had 2 mass units less than the starting 
material. This was identified as the 1,2,4-triazolo[4,3-c]pyrimidine (5) with the aid of 
correlation spectroscopy which showed NOE interactions between the pyrimidyl CH 
and the phenyl CHs ortho to the hydrazone bond. 
The many literature reports on the synthesis of the triazolopyrimidine fused ring 
system [11] either start form reaction of the pyrimidine hydrazine with an acid 
derivative (orthoformate [12] or activated acids [13]) or via oxidative cyclisation of 
the hydrazone with reagents like NBS [14], Pb(OAc)4 [15], FeCl3 [16], or 
iodobenzene diacetate [17]. 
On treatment of Exo2 (2) with sodium iodide and DMSO we were pleased to obtain a 
quantitative conversion to the triazole (6). 
 
Scheme 2. Sodium iodide catalysed oxidative cyclisation of Exo2 
We examine other salts as possible additives. As can be seen from Table 1, there is no 
measurable reaction at room temperature and the reaction was best performed at 
110°C.  Without additive, the oxidative cyclisation in DMSO is slow with low 
conversion.  
Table 1.  Influence of the salt on the oxidative cyclisation of Exo2 
 
 
salt time  
 
6
a
 
none 54hr 25% 
NaI 24hr >99% 
NaBr 48hr 31% 
b
 
NaCl 48hr 24% 
b
 
Na2SO4 48hr 24% 
KI 48hr >99% 
LiI 18hr >99% 
NMe4I 48hr >99% 
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2 and 6 are 
identified in the mixture, but also decomposition 
of the starting material. 
 
 
Other halide salts like sodium bromide were far less efficient than the iodide and 
sodium chloride was similar to the uncatalysed reaction in DMSO with a slow 
cyclisation and gradual decomposition at elongated reaction times. The other iodide 
salts tested all showed excellent ability for the cyclisation with lithium iodide being 
the most effective. The addition of excess lithium iodide does not notably enhance the 
rate, whereas the use of sub-molar quantities has a rate limiting effect. 
Table 2 details the effect of solvent choice on the oxidative cyclisation reaction of 
Exo2 (2) catalysed by lithium iodide. The most favourable conditions use DMSO or 
DMF with little reactivity seen in other common solvents though in several cases this 
is more likely due to the low solubility of the starting material and lower reaction 
temperatures. 
 
Table 2. Influence of the solvent on LiI catalysed oxidative cyclisation of Exo2 
 
Solvent 
LiI 
(equiv.) 
Time 2
a
  6
a
 
DMF 1 28hr -  78%
b 
DMF 0 48hr -  69%
b
 
DMSO 1 24hr - >99% 
DMSO 0 54hr 75% 25% 
MeOH 1 48hr >99% - 
EtOAc 1 48hr 83% 17% 
acetone 1 48hr >99% - 
ACN 1 48hr >95% <5%
 
ACN 0 48hr >99%
c
 + 
NO2CH3 1 48hr >99% - 
a
 ratio determined by NMR - 
b
 isolated yield - 
c 
precipitate collected and NMR recorded in DMSO(>80% 
recovery) 
 
 
Table 3 shows the range of pyrimidinylhydrazones 7a-e that can be cyclised to the 
1,2,4-triazolo[4,3-c]pyrimidines (8a-e) using lithium iodide in DMSO but the most 
convenient approach is to use lithium iodide in DMF. The triazole can simply be 
filtered off on cooling. The reported yields are unoptimised. The products are 
characterised by loss of the NH and imine hydrogen and the shift of the pyrimidine 
CH in 
1
H nmr. The 
1
H nmr and 
13
C nmr of the hydrazone (~8.3ppm/152ppm in the 
starting hydrazone) shift to around 9.1ppm [22] and 135ppm respectively in the 
cyclised products (8a-j). Spectra and physical properties also match the known 
derivatives 8a and 8b [18]. Additionally, we were fortunate to obtain suitable crystals 
for X-ray diffraction of 8b which confirmed the cyclised structure and the substitution 
pattern (Figure 2a). 
Table 3. Oxidative cyclisation of pyridyl- and pyrimidyl- hydrazones to 1,2,4-
triazolo[4,3-a]pyridines and 1,2,4-triazolo[4,3-a]pyrimidines 
 
S
N
N
NHN
OCH3
OH
S
N
N
NN
OH
OCH3
X equivalent LiI
110oC or reflux
2 6
 
 
 R1 R2 R3 X Product 
Conversion 
(DMSO) 
a 
Yield  
(DMF) 
b 
7a 
  
H N 8a - 76% 
7b 
  
H N 8b - 64% 
7c 
  
H N 8c 55%
 c 
- 
7d 
  
H N 8d >80% - 
7e 
  
H N 8e - 24% 
7f 
  
H N 8f - 52% 
7g 
  
H N 8g - 65% 
2 
  
H N 6 >99% 78% 
7h 
  
CH3 N 8h >80% - 
7i 
  
H N 8i 32% 
c
 - 
7j H-, H- 
 
H C 8j >99% - 
a 
Conversion determined by NMR - 
b
 Isolated yields -
 c 
further 
heating leads to decomposition of the reaction mixture.
 
 
We originally suspected that I2 was the reagent responsible for the cyclisation and that 
DMSO was the auxiliary oxidant generating the I2 from iodide [19]. I2 could act in an 
analogous manner to the reaction catalysed by NBS [14] and there is literature 
precedent for similar I2 catalysed cyclisations of diaiminobenzenes and aldehydes to 
benzimidazoles [20]. However, running the reaction under nitrogen does not yield the 
cyclisation, with or without lithium iodide highlighting the requirement for oxygen. 
This was also corroborated by the discovery that the cyclisation of Exo2 (2) proceeds 
in DMF alone to give 6 with out salt addition and that reaction of hydrazone 2 with 
iodine in DMSO does not give the expected cyclised product 6 (vida infra). This lead 
us to reassess our hypothesis and that may be oxygen and small amounts of base 
(DMF is known to breakdown on heating to carbon monoxide and dimethylamine) 
were responsible for the cyclisation with the role of the lithium iodide unclear. Other 
common amide solvents like dimethyl acetamide and N-methyl pyrrolidinone which 
are not prone to the same degradation as DMF, were not so effective in the additive 
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free cyclisation of Exo2 (2). The limitation of the additive free cyclisation reaction in 
DMF is that it is only practical for hydrazones with an activating hydroxy group on 
the aromatic ring with little or no cyclised material observed for reaction of the fluoro 
7c or ester 7d substituted hydrazones. These hydrazones require the presence of 
lithium iodide for efficient cyclisation. 
Returning to the effect of salts in DMSO, we next investigated basic salts. 
Heating Exo2 (2) in DMSO with sodium carbonate gave a new compound the 
isomeric triazole (9). The reaction also proceeds with sodium acetate but is not so 
effective. The pyrimidine CH of the 1,2,4-triazolo[1,5-c]pyrimidine now shifts further 
down field to 9.54ppm [12b], but the associated 
13
C signal still resonates around 
135ppm. No NOE effect could be measured between the pyrimidyl CH and the ortho 
protons of the hydrazone in accord with the different orientation of the phenyl group 
of the isomerised triazole.  The solid state structure of 9 from Xray crystallography is 
shown in Figure 2b confirming the substitution pattern of the triazole ring. 
 
Scheme 3. Oxidative cylisation and rearrangement of Exo2 with sodium carbonate 
Sodium carbonate has catalysed both the oxidative cyclisation and Dimroth [21] type 
rearrangement of (2) to yield the 1,2,4-triazolo[1,5-c]pyrimidine (9). We presume that 
the 1,2,4-triazolo[4,3-c]pyrimidine 6 is an intermediate which then undergoes the 
Dimroth type rearrangement. Small quantities of the triazole 6 can be observed by 
1
H 
nmr and thin layer chromatography as the reaction proceeds and the rearrangement of 
the triazole 6 to its isomeric1,2,4-triazolo[1,5-c] pyrimidine 9 is in accord with 
published work under similar basic conditions [12, 22]. 
The application of these basic conditions to the range of hydrazones to catalyse the 
oxidative cyclisation and rearrangement was followed by 
1
H nmr and is reported in 
Table 4.  
Table 4. Oxidative cyclisation of pyridyl- and pyrimidyl- hydrazones to 1,2,4-
triazolo[1,5-c]pyridines 8a-j and 1,2,4-triazolo[1,5-c]pyrimidines 10a-j 
 
 
 
 R1 R2 R3 X Time Product Ratio % 
a 
 
7a 
  
H N 2d
 b
 
7a 50% 
8a 50% 
10a - 
7b 
  
H N 2d
 b
 
7b 20% 
8b - 
10b 80% 
7c 
  
H N 5d
 b
 
7c 30% 
8c 5% 
10c 65% 
7d 
 
 
H N 24hr
 b
 
7d - 
8d - 
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10d >90% 
7g 
  
H N 4d 
7g - 
8g - 
10g >99% 
2 
  
H N 2d 
2 - 
6 - 
9 >99% 
7h 
  
CH3 N 3d 
7h - 
8h - 
10h >99% 
7i 
  
H N 4d
 b
 
7i 45% 
8i 10% 
10i 45% 
7j H-, H- 
 
H C 4d
 b
 
7j 45% 
8j 10% 
10j 45% 
a
 ratio determined by NMR - 
b
 further heating leads to decomposition 
 
In general, only compounds containing a 4-hydroxy group and a thiopyrimidine ring 
underwent efficient transformation to the1,2,4-triazolo[1,5-c]pyrimidines (9, 10g, and 
10h) but this is not so clear cut as the ester substituted hydazone 7d is a good 
substrate but the hydroxy containing phenylpyrimidine 7i reacts slowly. Following 
these reactions by 
1
H nmr, the initial cyclisation catalysed by sodium carbonate seems 
to be inefficient in some of these substrates and other reaction pathways start to 
predominate rather than the oxidative cyclisation and isomerisation to the 1,2,4-
triazolo[1,5-c]pyrimidine product. 
Investigation of the related reaction of amino imine 11 and aldehydes also furnishes 
the 1,2,4-triazolo[1,5-c]pyrimidines (9, 10a, 10c, 10g, and 10k) shown in Table 5.  
 
Table 5. Synthesis of 1,2,4-triazolo[1,5-c]pyrimidines 2, 10a, 10g and 10k starting 
from the amino imine 11. 
 
 
 
product R Yield 
9 
 
65% 
10a 
 
66% 
10c 
 
?? 
10g 
 
34% 
10k 
 
70% 
Similar cyclisations have been reported but required acetic acid catalysis [23]. 
The most practical procedure was simply to reflux equimolar amounts of the amino 
imine 11 and the required aldehyde in methanol. Salt addition is not required and 
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unlike the sodium carbonate oxidative cyclisation above, there are no constraints on 
the starting aldehyde nor the requirement to start from the hydrazone. Simple 
filtration gives good yields for both electron rich and electron deficient benzaldehydes 
and aliphatic aldehydes (Table 5).  
This reaction is very similar to the cyclisation reaction of 2 to 9 involving the 
cyclisation of an aldehyde derived intermediate and arial oxidation.  
 
The arial oxidation probably goes via a diamino acetal 12 as shown in scheme 4. 
There are several other examples of the arial oxidation of other dinitrogen containing 
heterocycles [3a, 24] and the benzylic nature and hydroxy substitution would all aid a 
radical oxidation. Adding a catalytic amount of AIBN to a salt free DMSO solution of 
hydrzaone 2 gave an increase in the amount of oxidative cyclisation product 6 
compared to DMSO strengthening the idea that the reaction goes by a radical 
oxidation. 
 
Scheme 4. Possible diamino acetal intermediate in the oxidative cyclisation of Exo2 
We finally looked at the reaction of 2 with an equivalent of iodine in DMSO which 
does lead to a rapid oxidative cyclisation but to the isomeric 1,2,4-triazolo[1,5-
c]pyrimidine with concomitant iodinisation to give isomer 15 based on the coupling 
constant between the two remaining hydrogens on the electron rich phenolic ring. 
 
Scheme 5. Iodine catalysed oxidation and rearrangement of Exo2 
Application of these conditions to the hydrazone 7a also gives the oxidative 
cyclisation and rearrangement to the triazole isomer 10a without the iodination of the 
less reactive phenyl ring. The generation of hydrogen iodide must catalyse the 
Dimroth type rearrangement of the intermediate 1,2,4-triazolo[4,3-c]pyrimidine to the 
isomeric 1,2,4-triazolo[1,5-c]pyrimidine ring system in a similar manner to other acid 
catalysed Dimroth rearrangement [12, 22, 23a, 25].  This again would indicate that the 
lithium iodide catalysed cyclisation does not involve the direct oxidation via 
elemental iodine. Iodide may reduce a peroxide intermediate from arial oxidation of 
the diamine precursor 12 or there may be a role for small amounts of iodine to 
mediate in the radical oxidation as has recently been described for the addition-
fragmentation chain transfer processes in living radical polymer synthesis [26]. 
 
3. Inhibition of Shiga toxin trafficking 
The new triazoles represent cyclised Exo2 derivatives that lack a potentially 
hydrolysable hydrazone linkage between the thienopyrimidine core and the phenyl 
substituent. Additionally, the different triazole isomers allow the presentation of the 
phenyl ring and its substituents in different orientations to optimise structure activity 
relationships accessing three alternative compounds from the one hydrazone starting 
material. The 1,2,4-triazolo[4,3-c]pyrimidines analogues 6, 8e, 8g and the 1,2,4-
triazolo[1,5-c]pyrimidines 9 and 10b (the other compounds were either too insoluble 
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or showed no meaningful activity in this assay) were tested in parallel for their 
inherent toxicity towards protein synthesis and also their ability to confer a protective 
effect on HeLa cells from a STx challenge in comparison to Exo2, by modifying a 
previously published procedure [9].  
Figure 2. Biological activity of the triazolopyrimidines 
 
Graph A – protein synthesis on treatment with compound (light grey bars) and on 
treatment with compound and STx (dark grey bars) normalised to carrier DMSO 
Graph B – protective effect as described by the ratio of protein synthesis in the 
presence of the test compound with and without STx challenge 
 
To summarise, the compounds were first assessed for their inherent cytotoxicity, 
based on the level of protein synthesis remaining in chemical-treated HeLa cells when 
normalised against protein synthesis levels in cell treated with the DMSO carrier 
alone (Figure 2 Graph A, light grey bars). The procedure was replicated but this time, 
the cells were challenged for 1 hour with a dose of Shiga toxin previously determined 
to promote a 60% drop in protein synthesis of the control, and the level of remaining 
protein synthesis measured (Figure 2 Graph A, dark gray bars). Most of the triazoles 
were substantially less toxic than Exo2 in this regard, although 10b inhibited protein 
synthesis significantly more than Exo2. When challenged with toxin, Exo2-treated 
cells almost completely retain their level of protein synthesis under these conditions 
(Graph A, light grey dark grey bars). The protective effect (Figure 2 Graph B) is 
quantified by comparing protein synthesis from exposure to just the compound with 
protein synthesis after treatment with the compound and a toxin challenge, and takes 
into account any effect of the compound alone. All of the triazoles examined were 
less effective in this comparison than Exo2. The loss of an NH hydrogen bond 
donating group of the hydrazone linkage and the tethering of the substituted phenyl 
group into a triazole ring may significantly alter the orientation of the phenyl ring 
from that adopted as a hydrazone in Exo2 and any advantages from using non-
hydrolysable analogues is not revealed under these conditions. 
 
 
4. Conclusions. 
 
In conclusion, mild and simple conditions have been discovered to produce 
the oxidative cyclisation of pyrimidine hydrazones to 1,2,4-triazolo[4,3-c]pyrimidines 
by heating in DMSO or DMF. Lithium iodide is required for efficient cyclisation of 
starting hydrazones that lack an activating 4-hydroxyphenyl substituent and no further 
isomerisation takes place under these conditions. These triazoles undergo 
rearrangement to the isomeric 1,2,4-triazolo[1,5-c]pyrimidines using sodium 
carbonate in DMSO or can be furnished directly from oxidative cyclisation and 
rearrangement of some appropriately substituted starting hydrazones. A more general 
complementary procedure as exemplified by the synthesis of the 1,2,4-triazolo[1,5-
c]pyrimidines 9, 10a, 10c, 10g, and 10k starting from the amino imine 11 was also 
realised.  
Although we have been unable to elucidate a mechanism, the reactions discussed 
above allow routes to specific triazolopyrimidine isomers from aldehyde precursors 
by simple arial oxidation. 
These triazoles were tested in a toxin challenge assay in comparison to Exo2. 
Although most showed a reduced level of inhibition of protein synthesis than Exo2, 
they were less effective in giving a protective effect against Shiga toxin than Exo2 in 
this assay. 
Whether they protect against alternative toxins that follow the retrograde pathway was 
not investigated here. Nevertheless, the novel compounds described in this report may 
provide a valuable platform for future studies. 
 
5.1 Experimental 
All reagents and solvents were purchased from Lancaster and Aldrich and 
used without further purification. The hydrazone starting materials were synthesised 
as detailed elsewhere [9]. NMR spectra were recorded on a DPX-400 spectrometer at 
room temperature (298K). The spectra were recorded in parts per million (ppm) and 
referenced using residual protio solvents relative to trimethylsilane standard (δH = 
0ppm). 2D COSY, HMQC, HMBC  and NOSEYspectra were used to aid with peak 
assignments. ESI mass spectra were obtained using a Bruker Esquire 2000 mass 
spectrometer coupled with an Agilent 1100 HPLC (without a column) as the delivery 
system. Accurate mass spectra were obtained using a Bruker micro-TOF ESI attached 
to a time of flight (TOF) analyzer.  Infrared spectra were gathered using a Perkin-
Elmer Paragon 1000 FTIR spectrometer. CHN elemental analyses were carried out by 
Warwick Analytical Services. Thin Layer Chromatography used in monitoring 
reaction progress were performed using silica layer (0.25mm) coated alumina plates. 
Weights were recorded on a balance to 4 decimal places.   
 
5.1.1 General procedure for lithium iodide catalysed oxidative cyclisation of 
pyrimidyl hydrazones to give the 1,2,4-triazolo[4,3-c]pyrimidines (6,7a-e) 
 
The hydrazone (5mmole) was dissolved in reagent grade DMF (15ml) and one 
equivalent of lithium iodide was added (1 equivalent, 0.7g). The mixture was stirred 
and heated at 110°C under an air atmosphere. After the specified time (24 or 48hrs), 
the reaction was allowed to cool and the precipitate isolated by filtration and washed 
with a little methanol and then diethyl ether and dried under high vacuum. 
 
5.1.1.1 3-(4-Hydroxy-3-methoxyphenyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-
e][1,2,4]triazolo[4,3-c]pyrimidine 6 
1
H NMR (400 MHz, DMSO) δ: 1.93 (m, 4H, 2 CH2), 3.12 (m, 2H, CH2), 3.35 (m, 2H, 
CH2), 3.90 (s, 3H, OCH3), 7.02 (d, J = 8.0Hz, 1H, CH), 7.39 (dd, J1 = 8.0Hz, J2 = 
2.0Hz, 1H, CH), 7.50 (d, J = 2.0Hz, 1H, CH), 9.20 (s, 1H, CH), 9.69 (brs, 1H, OH). 
13
C NMR (100 MHz, DMSO) δ: 21.7 (CH2), 22.5 (CH2), 24.8 (CH2), 25.2 (CH2), 55.8 
(OCH3), 112.4 (CH), 115.9 (CH), 116.6 (C), 117.8 (C), 121.8 (CH), 129.2 (C), 134.5 
(CH), 137.7 (C), 146.0 (C), 146.1 (C), 148.0 (C), 148.7 (C), 148.8 (C). ES-MS m/z 
353.1 (MH
+
). HRMS 353.1067, found 353.1068. Anal. Calcd for C18H16N4O2S: C 
61.35, H 4.68, N 15.90; found: C 60.35, H 4.51, N 15.57. 
 
5.1.1.2 3-Phenyl-8,9,10,11-tetrahydro[1]benzothieno[3,2-e][1,2,4]triazolo[4,3-
c]pyrimidine 8a  
1
H NMR (400 MHz, DMSO) δ: 1.94 (m, 4H, 2 CH2), 2.93 (m, 2H, CH2), 3.13 (m, 2H, 
CH2), 7.66 (m, 3H, 3 CH), 8.01 (m, 2H, 2 CH), 9.22 (s, 1H, CH). 
13
C NMR (100 
MHz, DMSO) δ: 21.7 (CH2), 22.5 (CH2), 24.8 (CH2), 25.2 (CH2), 117.8 (C), 125.9 
(C), 128.6 (4 CH), 128.6 (C), 129.2 (C), 129.3 (CH), 130.4 (CH), 137.9 (C), 145.8 
(C), 146.3 (C). ES-MS m/z 307.1 (MH
+
). HRMS 307.1012, found 307.1015.  
 
5.1.1.3 3-(4-methoxyphenyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-
e][1,2,4]triazolo[4,3-c]pyrimidine 8b 
1
H NMR (400 MHz, DMSO) δ: 1.93 (m, 4H, 2 CH2), 2.93 (m, 2H, CH2), 3.12 (m, 2H, 
CH2), 3.89 (s, 3H, OCH3), 7.19 (d, J = 8.8Hz, 2H, CH), 7.93 (d, J = 8.8Hz, 2H, CH), 
9.16 (s, 1H, CH). 
13
C NMR (100 MHz, DMSO) δ: 21.7 (CH2), 22.5 (CH2), 24.8 
(CH2), 25.1 (CH2), 55.4 (OCH3), 114.7 (CH), 117.8 (C), 118.1 (C), 129.2 (C), 130.2 
(CH), 134.3 (CH), 137.8 (C), 145.7 (C), 146.1 (C), 148.8 (C), 160.8 (C). ES-MS m/z 
337.1 (MH
+
). HRMS 337.1118, found 337.1108.  
 
5.1.1.4 3-(3-Hydroxyphenyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-
e][1,2,4]triazolo[4,3-c]pyrimidine 8e 
1
H NMR (300 MHz, DMSO) δ: 1.94 (m, 4H, 2 CH2), 2.94 (m, 2H, CH2), 3.13 (m, 2H, 
CH2), 7.03 (d, J = 7.6Hz, 1H, CH), 7.36 (s, 1H, CH), 7.43 (m, 2H, 2 CH), 9.18 (s, 1H, 
CH), 9.92 (brs, 1H, OH). 
13
C NMR (75 MHz, DMSO) δ: 21.7 (CH2), 22.5 (CH2), 24.8 
(CH2), 25.1 (CH2), 115.3 (CH), 117.5 (CH), 117.6 (C), 119.0 (CH), 126.9 (C), 129.2 
(C), 130.4 (CH), 134.3 (CH), 137.9 (C), 145.8 (C), 146.3 (C), 148.9 (C), 157.9 (C). 
ES-MS m/z 323.1 (MH
+
). HRMS 323.0961, found 323.0959.  
 
5.1.1.5 3-(2-Hydroxyphenyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-
e][1,2,4]triazolo[4,3-c]pyrimidine 8f 
hot NMR 
ES-MS m/z 323.1 (MH
+
). HRMS 323.0961, found 323.0956. Anal. Calcd for 
C17H14N4OS: C 63.33, H 4.38, N 17.38; found: C 62.97, H 4.39, N 17.17. 
 
 
5.1.1.6 3-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-e] 
[1,2,4]triazolo[4,3-c]pyrimidine 8g  
1
H NMR (400 MHz, DMSO) δ: 1.92 (m, 4H, 2 CH2), 2.91 (m, 2H, CH2), 3.10 (m, 2H, 
CH2), 7.01 (d, J = 8.6Hz, 2H, 2 CH), 7.81 (d, J = 8.6Hz, 2H, 2 CH), 9.14 (s, 1H, CH), 
10.12 (brs, 1H, OH). 
13
C NMR (100 MHz, DMSO) δ: 21.7 (CH2), 22.5 (CH2), 24.8 
(CH2), 25.1 (CH2), 116.0 (CH), 116.4 (C), 117.8 (C), 129.2 (C), 130.2 (CH), 134.3 
(CH), 137.7 (C), 145.9 (C), 146.0 (C), 148.7 (C), 159.4 (C). ES-MS m/z 323.1 (MH
+
). 
HRMS 323.0961, found 323.0970.  
 
5.1.1.7 3-(4-Hydroxy-3-methoxyphenyl)-5-methyl-8,9,10,11-
tetrahydro[1]benzothieno[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine 8h 
1
H NMR (400 MHz, DMSO) δ: 1.87 (m, 4H, 2 CH2), 2.23 (m, 2H, CH2), 2.86 (m, 2H, 
CH2), 3.05 (s, 3H, CH3), 3.79 (s, 3H, OCH3), 6.92 (d, J = 8.0Hz, 1H, CH), 7.07 (dd, 
J1 = 8.0Hz, J2 = 2.0Hz, 1H, CH), 7.24 (d, J = 2.0Hz, 1H, CH), 9.55 (brs, 1H, OH). 
ES-MS m/z 367.1 (MH
+
). 
 
5.1.1.8  3-(4-Hydroxy-3-methoxyphenyl)-1,2,4-triazolo[4,3-c]pyrimidine, 8j 
1
H NMR (400 MHz, DMSO) δ: 3.88 (s, 3H, OCH3), 7.01 (t, J = 7.0Hz, 1H, CH), 7.04 
(d, J = 8.3Hz, 1H, CH), 7.30 (d, J = 8.3Hz, 1H, CH), 7.42 (m, 2H, 2 CH), 7.83 (d, J = 
7.0Hz, 1H, CH), 8.55 (d, J = 7.0Hz, 1H, CH), 9.72 (s, 1H, CH). 
13
C NMR (100 MHz, 
DMSO) δ: 55.7 (OCH3), 111.7 (CH), 112.1 (C), 114.3 (CH), 115.4 (CH), 115.9 (CH), 
117.2 (C), 121.1 (CH), 124.0 (CH), 127.8 (CH), 146.3 (C), 148.4 (C), 149.5 (C). ES-
MS m/z 242.0 (MH
+
). 
 
5.1.2 General procedure for oxidative cyclisation of amino imime 11with aldehydes to 
give the 1,2,4-triazolo[1,5-c]pyrimidines (9,10a,c,g,k) 
 
 To a solution of the amino imine 11 [12, 22] (0.25g, 1.13mmol) in methanol 
(10ml) was added the required aldehyde (1.1 equivalents) and the mixture strirred and 
heated at reflux overnight. On cooling, the precipitate was isolated by filtration and 
the solid washed with cold methanol and dried under high vacuum to give the yields 
shown in Table 5. 
 
 
5.1.2.1 2-(4-Hydroxy-3-methoxyphenyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-
e][1,2,4]triazolo[1,5-c]pyrimidine 9  
1
H NMR (400 MHz, DMSO) δ: 1.91 (m, 4H, 2 CH2), 2.90 (m, 2H, CH2), 3.09 (m, 2H, 
CH2), 3.90 (s, 3H, OCH3), 6.95 (d, J = 7.8Hz, 1H, CH), 7.70 9 (s, 1H, CH), 7.71 (d, J 
= 7.8Hz, 1H, CH), 9.54 (s, 1H, CH), 9.61 (brs, 1H, OH). 
13
C NMR (100 MHz, 
DMSO) δ: 21.6 (CH2), 22.4 (CH2), 24.8 (CH2), 24.9 (CH2), 55.6 (OCH3), 110.4 (CH), 
115.7 (CH), 119.2 (C), 120.8 (CH), 120.9 (C), 128.5 (C), 135.0 (CH), 137.7(C), 147.8 
(C), 148.8 (C), 149.2 (C), 152.6 (C), 164.1 (C). ES-MS m/z 353.1 (MH
+
). HRMS 
353.1067, found 353.1069. Anal. Calcd for C18H16N4O2S: C 61.35, H 4.68, N 15.90; 
found: C 59.69, H 4.60, N 15.43. 
 
5.1.2.2 2-Phenyl-8,9,10,11-tetrahydro[1]benzothieno[3,2-e][1,2,4]triazolo[1,5-
c]pyrimidine 10a 
hot NMR 
ES-MS m/z 307.1 (MH
+
). HRMS 307.1012, found 307.1012. Anal. Calcd for 
C17H14N4S: C 66.64, H 4.61, N 18.29, S 10.47; found: C 66.08, H 4.60, N 18.00, S 
10.26. 
 
 
5.1.2.3   2-(4-Fluorophenyl-8,9,10,11-tetrahydro[1]benzothieno[3,2-
e][1,2,4]triazolo[1,5-c]pyrimidine 10c  
1H NMR (400 MHz, DMSO) δ: 1.92 (m, 4H, 2 CH2), 2.92 (m, 2H, CH2), 3.11 (m, 2H, 
CH2), 7.40 (t, JHH = 
3
JHF = 8.8Hz, 2H, 2 CH), 8.27 (t, JHH = 
3
JHF = 8.8Hz, 2H, 2 CH), 
9.62 (s, 1H, CH). 
13C NMR (100 MHz, DMSO) δ: 21.6 (CH2), 22.4 (CH2), 24.7 (2 
CH2), 116.0 (CH, 
2
JCF = 21.8Hz), 125.2 (C), 126.4 (C), 128.5 (C), 129.4 (CH, 
3
JCF = 
8.9Hz), 136.9 (CH), 137.2 (C), 138.1 (C), 148.5 (C), 152.7 (C), 162.9 (C). ES-MS m/z 
325.0 (MH
+
). HRMS 235.0918, found 325.0914. 
 
5.1.2.4 2-(4-Hydroxyphenyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-
e][1,2,4]triazolo[1,5-c]pyrimidine 10g  
1H NMR (400 MHz, DMSO) δ: 1.93 (m, 4H, 2 CH2), 2.94 (m, 2H, CH2), 3.15 (m, 2H, 
CH2), 6.95 (d, J = 8.6Hz, 2H, 2 CH), 8.10 (d, J = 8.6Hz, 2H, 2 CH), 9.59 (s, 1H, CH), 
10.02 (brs, 1H, OH).  
13C NMR (100 MHz, DMSO) δ: 21.7 (CH2), 22.5 (CH2), 24.9 (CH2), 25.0 (CH2), 
115.6 (CH), 119.3 (C), 120.6 (C), 128.6 (C), 128.7 (CH), 136.8 (CH), 137.8 (C), 
148.9 (C), 152.7 (C), 159.8 (C), 164.1 (C). ES-MS m/z 365.1 (MNa
+
). HRMS 
365.1043, found 365.1056.  
 
5.1.2.5   2-(2-Methylpropyl)-8,9,10,11-tetrahydro[1]benzothieno[3,2-
e][1,2,4]triazolo[1,5-c]pyrimidine 10k  
1
H NMR (400 MHz, DMSO) δ: 0.98 (d, J = 6.8Hz, 6H, 2 CH3), 1.89 (m, 4H, 2 CH2), 
2.20 (m, 1H, CH), 2.51 (d, J = 6.8Hz, 2H, CH2), 2.90 (m, 2H, CH2), 3.04 (m, 2H, 
CH2), 9.52 (s, 1H, CH). 
hot NMR for 13C? 
ES-MS m/z 287.1 (MH
+
). HRMS 287.1325, found 287.1326.  
 
5.2  Toxin challenge assay 
 
HeLa cells were pretreated for 30 minutes with growth medium containing 50μM 
Exo2 or triazole diluted from a 50 mM stock in DMSO or with vehicle DMSO alone, 
and were then challenged or not for 1h with 50 ng/ml STx in growth medium 
containing Exo2, compound or DMSO as appropriate. Under these conditions, trial 
experiments had established that this dose of toxin reduced protein synthesis ability of 
HeLa cells to 40% of that of non-toxin-treated controls. The remaining ability of the 
cells to manufacture protein was then assessed by incubating the cells for 30 minutes 
in PBS containing [
35
S]-labelled methionine and cysteine, and measuring 
incorporation of these into acid-precipitable material[9]. The error bars are +/- 1.S.D. 
 
5.3  Crystallography 
Suitable crystals of 8b, 9 and 10k were grown by slow diffusion of methanol into a 
DMSO solution of the compound in an nmr tube. 
The crystals were mounted in oil and the data recorded at 100K using an Oxford 
Diffraction Gemini four-circle system with Ruby CCD area detector. 
The data was solved and refined using the SHELXTL suite of programs [27]. 
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